Encore is NEXUS between respiratory therapy, outcomes

LIVINGSTON, Tenn. – With more than 27,000 patients now managed through NEXUS, Encore Healthcare was able to publish studies in CHEST and other journals recently that show its respiratory therapy management software improves outcomes. 

Among the key take-aways from the studies: NEXUS can reduce hospital admissions by about 60% and it can improve medication management by about 41%. 

“We’re at a tipping point,” said Zach Gantt, CEO of Encore Healthcare. “We have enough market penetration now to recognize that tracking outcomes is the way to manage patients in the DME space.” 

NEXUS provides a platform for providers to not only monitor equipment but also assess patient progress, intervene with clinical protocols, instruct and improve self-management, and apply analytics to report outcomes. 

To date, Encore has had the most traction with providers serving patients on ventilators, including AeroCare and AdaptHealth, but it’s now seeing more and more providers leverage NEXUS for patients on nebulizers and oxygen therapy. 

“The industry is shifting back to a respiratory focus, so while we started with a small subset of providers focusing on vents, we now have nebulizer and oxygen programs and so many more vent programs,” Gantt said. “The sky is the limit.” 

For Gantt, who grew up in the industry fixing oxygen concentrators at 12 and making deliveries at 16, helping providers generate outcomes and use them to not only improve patient care but also snag exclusive contracts and partnerships is a game changer. 

“Our passion and what really drives us is knowing providers can be more than they are,” he said. “We’re part of the solution that’s allowing them to be more of a player in value-based models.”